Kidney Week 2012 Anemia
Once-monthly injections of peginesatide are as effective as one to three injections per week of epoetin in maintaining hemoglobin levels.
Hematocrit decreases as estimated glomerular filtration rate (eGFR) declines in hypertensive chronic kidney disease (CKD) patients.
Patients initiating daily hemodialysis (DHD) face a significant decrease in mean hemoglobin (Hb), hematocrit, and transferrin.
Intravenous ascorbic acid (IVAA) can be a potent and effective adjuvant treatment for hemodialysis patients who have normoferritinemic anemia resistant to treatment with erythropoietin (EPO).
Epoetin use and hemoglobin (Hb) levels have declined similarly for black and non-black dialysis patients following the advent of Medicare’s system of “bundled” payments.
Iron deficiency in the absence of anemia is associated with intradialytic hypotension (IDH), a finding that suggests iron has a role beyond erythropoiesis.
Clinicians are prescribing less erythropoietin and more intravenous iron for anemic hemodialysis patients after the introduction of a prospective payment system (PPS) for dialysis services (“bundling”) and changes to ESA drug labels.
Variant hemoglobin (Hb) is common in African-American hemodialysis patients and it is associated with a need for significantly increased doses of ESA.
Dosing intravenous (IV) iron at higher TSAT levels has only a modest effect on raising transferrin saturation (TSAT), ferritin, and hemoglobin in anemic hemodialysis patients.
Bolus dosing of intravenous (IV) iron is associated with an elevated risk of infection-related hospitalization among anemic hemodialysis (HD) patients compared with maintenance dosing.
Want to read more?
Please login or register first to view this content.
Next post in Kidney Week 2012 Anemia